Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine wether activated and expanded autologous Natural
Killer cells (NKAEs) are effective in the treatment of patients with multiple myeloma on
second or later relapse. NKAEs are used in combination with anti-myeloma drugs such as
lenalidomide or bortezomib.